Inspire Medical price target lowered to $64 from $70 at Truist

Truist lowered the firm’s price target on Inspire Medical (INSP) to $64 from $70 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds however that the stock’s discount relative to its peers is justified given the uncertainty around the company’s near-term growth profile, which includes a decelerating domestic growth trajectory associated with reimbursement friction.